

# Clinical trials of aspirin + dipyridamol

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>aspirin + dipyridamol vs placebo</b>			
<a href="#">Hess (2) , 1985</a> n=80/80 follow-up:	Aspirine Dipyridamole 330 mg / j 225 mg / j versus Placebo	patients with occlusive arterial disease in the lower extremities	Parallel groups double blind
<a href="#">Schoop (2) , 1983</a> n=100/100 follow-up:	Aspirine Dipyridamole 990 mg / j 225 mg /j versus Placebo	AOMI stade non prcis	Parallel groups double blind
<a href="#">VA study , 1986</a> n=110/121 follow-up: 46 months	Aspirine + Dipyridamole 975 mg / j 225 mg /j versus Placebo	non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene	Parallel groups double blind

More details and results :

- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>

## References

### Hess (2), 1985:

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Hess H, Mietaschk A, Deichsel G Lancet 1985 Feb 23;1:415-9 [[2857803](#)]

### Schoop (2), 1983:

W Schoop, H Levy. prevention of peripheral arterial occlusive disease with antiaggregants. Thromb Haemost 1983, 30: 137.

### VA study, 1986:

Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Colwell JA, Bingham SF, Abaira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F Diabetes Care 1986 Mar-Apr;9:140-8 [[3516608](#)]

## 2 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
<b>aspirin + dipyridamol vs placebo</b>			
<a href="#">Prandoni , 1991</a> n=44/44 follow-up: 12m	Aspirin 50mg/d + Dipyridamol 400mg/d versus placebo	patients with acute unstable angina	double blind

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>

## References

### Prandoni, 1991:

Prandoni P, Milani L, Barbiero M, Cardaioli P, Sanson A, Barbaresi F, Zonzin P, Visani L [Treatment of unstable angina with dipyridamole combined with low doses of aspirin. A multicenter pilot double-blind controlled study] *Minerva Cardioangiolog* 1991;39:267-73 [[1780077](#)]

## 3 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
<b>aspirin + dipyridamol vs control</b>			
<a href="#">Chicago , 1982</a> n=12/15 follow-up:	aspirin, 300 mg bid, and dipyridamole, 75 mg tid versus control	patients with acute spinal cord injury	Parallel groups open
<b>aspirin + dipyridamol vs no treatment</b>			
<a href="#">Morris-B , 1977</a> n=32/32 follow-up:	Aspirin 900 mg daily + dipyridamole versus control	elderly patients with hip fractures	Parallel groups open
<a href="#">Lyon-I , 1975</a> n=20/20 follow-up: 2 weeks	Aspirin 1500 mg daily + Dipyridamole versus control	Elective orthopaedic surgery	

continued...

Trial	Treatments	Patients	Trials design and methods
<b>aspirin + dipyridamol vs placebo</b>			
<b>Encke-II , 1976</b> n=34/25 follow-up:	Aspirin 1500mg daily, Aspirin 990mg daily + dipyridamol versus placebo	patients with abdominal operations	Parallel groups double-blind
<b>Hamburg , 1976</b> n=21/11 follow-up: 3 weeks	A+Dipyridamole,A1000 versus placebo	Elective orthopaedic surgery	
<b>Frankfurt , 1981</b> <i>unpublished</i> n=25/14 follow-up:	A+Dip,A1320 versus placebo	patients with myocardial infarction	Parallel groups double-blind

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- antiplatelets drug for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q186>
- antiplatelets drug for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q462>
- antiplatelets drug for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q463>
- antiplatelets drug for thrombosis prevention in elective orthopedic surgery at <http://www.trialresultscenter.org/go-Q464>

## References

### Chicago, 1982:

Green D, Rossi EC, Yao JS, Flinn WR, Spies SM Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. Paraplegia 1982;20:227-34 [6813814]

### Morris-B , 1977:

Morris GK, Mitchell JR Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. Br Med J 1977;1:535-7 [843794]

### Lyon-I, 1975:

Dechavanne M, Ville D, Viala JJ, Kher A, Faivre J, Pousset MB, Dejour H Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis 1975;4:94-100 [1205340]

### Encke-II , 1976:

Encke A, Stock C, Dumke HO [Double-blind study for the prevention of postoperative thrombosis] Chirurg 1976;47:670-3 [1001131]

**Hamburg, 1976:**

Boehringer Ingelheim DVT nach Hirntumoroperationen Boehringer Ingelheim, 1976. (Internal report.)

**Frankfurt, 1981:**

unpublished

Boehringer Ingelheim. Asasantin DVT nach myokardinfarkt Bracknell Berkshire: Boehringer Ingelheim, 1981. (Internal report.)

**4 CABG surgery**

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>aspirin + dipyridamol vs control</b>			
<b>Pantely , 1979</b> n=18/30 follow-up: 6m	aspirin 325 mg three times a day + dipyridamole 75 mg three times a day versus control	patients undergoing aortocoronary saphenous-vein bypass-graft surgery	open
<b>Brussels , 1987</b> n=24/25 follow-up: 12m	-	-	
<b>Czech , 1986</b> n=47/46 follow-up: 12m	aspirin 1000 + dipiridamol 225 versus control (no medication)	Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less	open
<b>Des Moines , 1980</b> n=60/54 follow-up: 12m	-	-	
<b>aspirin + dipyridamol vs placebo</b>			
<b>GESIC (aspirin+dipyridamol) , 1990</b> n=368/371 follow-up: 28d	aspirin 50 mg + dipyridamole 75mg 3 times daily versus placebo	patients undergoing CABG	Parallel groups double blind Spain
<b>Brooks , 1985</b> n=160/160 follow-up: 12m	aspirin 990 mg and dipyridamole 225 mg daily versus placebo	patients undergoing coronary bypass grafting	double blind
<b>Mayo-A , 1984</b> n=202/205 follow-up: 12m	aspirin 975 + dipiridamol 225 versus placebo	patients undergoing coronary bypass grafting	double blind

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Wadsworth , 1985</b> n=96/102 follow-up: 12m	aspirin 975 mg/d + dipyridamol 225 mg/d, aspirin 975 mg/d versus placebo	coronary bypass patients	double blind
<b>Basel , 1989</b> n=62/63 follow-up: 9m	aspirin 50 + dipyridamol 400 versus placebo	patients who had aortocoronary vein bypass surgery	double blind
<b>Leeds-B , 1985</b> n=61/64 follow-up: 6m	aspirin 990 + dipyridamol 225 (W) versus placebo	patients undergoing aorta-coronary bypass grafting for disabling angina	double blind
<b>Thaulow , 1987</b> n=34/35 follow-up: 3m	aspirin 975 + dipyridamol 225 versus placebo	Patients scheduled to receive at least three aortocoronary venous bypass grafts	double blind

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

## References

### **Pantely, 1979:**

Pantely GA, Goodnight SH Jr, Rahimtoola SH, Harlan BJ, DeMots H, Calvin L, Rsch J Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med 1979;301:962-6 [386118]

### **Brussels, 1987:**

Lavenne-Pardonge E, Col-de Beys C, Dion R, Ponlot R, Moriau M.A Effect of antiaggregant on occlusion of saphenous graft coronary bypass Thromb Haemost 1987;58:547 (Abstract 2024)

### **Czech, 1986:**

Pirk J, Vojcek J, Kovc J, Fabin J, Firt P Improved patency of the aortocoronary bypass by antithrombotic drugs. Ann Thorac Surg 1986;42:312-4 [3489445]

### **Des Moines, 1980:**

Klotz L Antiplatelet and anticoagulant therapy after coronary bypass. N Engl J Med 1980;302:866 [6965764]

### **GESIC (aspirin+dipyridamol), 1990:**

Sanz G, Pajarn A, Alegria E, Coello I, Cardona M, Fournier JA, Gmez-Recio M, Ruano J, Hidalgo R, Medina A Circulation 1990;82:765-73 [2203555]

### **Brooks, 1985:**

Brooks N, Wright J, Sturridge M, Pepper J, Magee P, Walesby R, Layton C, Honey M, Balcon R Randomised placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. Br Heart J 1985;53:201-7 [3881108]

### **Mayo-A, 1984:**

Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984;310:209-14 [6361561]

**Wadsworth, 1985:**

Brown BG, Cukingnan RA, DeRouen T, Goede LV, Wong M, Fee HJ, Roth JA, Carey JS Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. *Circulation* 1985;72:138-46 [3874009]

**Basel, 1989:**

Pfisterer M, Burkart F, Jockers G, Meyer B, Regenass S, Burckhardt D, Schmitt HE, Miller-Brand J, Skarvan K, Stulz P Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. *Lancet* 1989;2:1-7 [2567792]

**Leeds-B, 1985:**

Rajah SM, Salter MC, Donaldson DR, Subba Rao R, Boyle RM, Partridge JB, Watson DA Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial. *J Thorac Cardiovasc Surg* 1985;90:373-7 [3897722]

**Thaulow, 1987:**

Thaulow E, Frysaker T, Dale J, Vatne K Failure of combined acetylsalicylic acid and dipyridamole to prevent occlusion of aortocoronary venous bypass graft. *Scand J Thorac Cardiovasc Surg* 1987;21:215-20 [3501902]

## 5 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
<b>aspirin + dipyridamol vs placebo</b>			
<b>Hess (2) , 1985</b> n=80/80 follow-up:	Aspirine Dipyridamole 330 mg / j 225 mg / j versus Placebo	patients with occlusive arterial disease in the lower extremities	Parallel groups double blind
<b>Schoop (2) , 1983</b> n=100/100 follow-up:	Aspirine Dipyridamole 990 mg / j 225 mg /j versus Placebo	AOMI stade non precis	Parallel groups double blind
<b>VA study , 1986</b> n=110/121 follow-up: 46 months	Aspirine + Dipyridamole 975 mg / j 225 mg /j versus Placebo	non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>

## References

**Hess (2), 1985:**

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Hess H, Mietaschk A, Deichsel G Lancet 1985 Feb 23;1:415-9 [2857803]

**Schoop (2), 1983:**

W Schoop, H Levy. prevention of peripheral arterial occlusive disease with antiaggregants. Thromb Haemost 1983, 30: 137.

**VA study, 1986:**

Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Colwell JA, Bingham SF, Abaira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F Diabetes Care 1986 Mar-Apr;9:140-8 [3516608]

## 6 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
<b>aspirin + dipyridamol vs placebo</b>			
Schwartz (Toronto) , 1988 n=187/189 follow-up: 6m	aspirin 990 + D225 (H) versus placebo	-	Parallel groups double blind Canada
White (aspirin+dipiridamol) , 1991 n=245/254 follow-up: 6m	-	-	Parallel groups
Nye (Dunedin) , 1990 n=35/37 follow-up: 12m	aspirin 300 + D225 versus placebo	-	Parallel groups NA
Mayo-PTCA , 1989 n=102/105 follow-up: 48h	-	-	Parallel groups

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>

## References

**Schwartz (Toronto), 1988:**

Schwartz L, Bourassa MG, Lesprance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9 [2967433]

**White (aspirin+dipyridamol), 1991:**

White CW, Chaitman B, Knudtson ML, Chisholm RJ, and the Ticlopidine Study Group. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial *Coronary Artery Dis* 1991;2:757-67

**Nye (Dunedin), 1990:**

Nye ER, Ablett MB, Robertson MC, Ilsley CD, Sutherland WH Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. *Aust N Z J Med* 1990;20:549-52 [[222347](#)]

**Mayo-PTCA, 1989:**

Chesebro JH, Webster MW, Reeder GS, Mock MB, Grill DE, Bailey KR, et al. Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis *Circulation* 1989;80 (suppl II):II-64 (Abstract 0257)

Entry terms: dipyridamol, dipyridamole monoacetate, dipyridamol monoacetate,